All In Biotech

Drug Trial Radar · NCT07198347

Efficacy and Safety of AG2001 in Patients With Acute Bronchitis

A Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2001 in Patients With Acute Bronchitis

Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Nov 1, 2025

Primary completion

Mar 31, 2026

Study completion Oct 31, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double-blind, active-controlled clinical trial designed to evaluate the efficacy and safety of AG2001 in patients with acute bronchitis. The primary objective is to demonstrate the superiority of AG2001 over two active comparators based on the change in Bronchitis Severity Score (BSS) at Day 4.

Conditions

  • Acute Bronchitis

Interventions

  • AG2001Drug

    Oral administration, three times daily for 7 days.

  • AG20011Drug

    Oral administration, three times daily for 7 days.

  • AG20012Drug

    Oral administration, three times daily for 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Bronchitis Severity Score (BSS) from Baseline to Day 4Time frame: Baseline to Day 4

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.